Jaguar Health's Crofelemer Reduces Daily Parenteral Support Needs by About 15% in Infant With Congenital Sodium Diarrhea

Bitget2026/10/21 13:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Jaguar Health reported reduced intravenous nutritional support needs with oral crofelemer in an infant with intestinal failure caused by congenital sodium diarrhea.
Treatment was well tolerated, with no significant clinical or laboratory abnormalities during the first several weeks.
The findings extend crofelemer's observed benefit to a third intestinal failure-related disorder under expanded access.
Earlier findings presented in June 2026 showed reduced support needs in pediatric microvillus inclusion disease and short bowel syndrome.
A US approval application for microvillus inclusion disease is planned for mid-2027; the ongoing pivotal trial has completed enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jaguar Health Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610210900ACCESSWRNAPR_____1239113) on October 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Jaguar Health's Crofelemer Reduces Daily Parenteral Support Needs by About 15% in Infant With Congenital Sodium Diarrhea

You may also like

Crypto prices